Vote Scores
Filings read through

How funds voted at Revance Therapeutics, Inc.

Filers reporting
268, year to 30 June 2024
Latest meeting on file
Meetings on file
1

In the year to 30 June 2024, 268 filers on Form N-PX reported votes at Revance Therapeutics, Inc.. The votes fall in one meeting. The figures count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting. Filers gave 415 marks to the ballot items, each with or against management. 77.8% of the marks are with management.

On say-on-pay, 69 of the 249 reporting filers that marked the item voted against management. This is 27.7% of the filers. Of the reported shares, 19.8% went against management. The median of the 3,781 companies on this site with a say-on-pay item is 7.5% of filers and 2.9% of reported shares.

At the meeting of 1 May 2024, 28 fund families have a say-on-pay position with management and 10 have a position against management.

By filers reporting in the year to 30 June 2024, Revance Therapeutics, Inc. was number 2,019 of 11,775 companies with a page and votes in that year. In all seasons on file, category SECTION 14A SAY-ON-PAY VOTES is 39.8% of the vote records at Revance Therapeutics, Inc.. At all companies on this site, it is 12.3%.

ForAgainstAbstain, withhold or otherAmber tick: the part cast against management

If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.

The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .

The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.

The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.

The page gives records. It gives no investment advice and no advice on how to vote.

Season on this page: year to 30 June 2024. Filings read through . How the figures are made

Since the last update

The site has recorded no change in the tracked figures of this page.

Tracked: the meetings on file and the date of the latest meeting. All recorded changes

The ballot of 1 May 2024

266 filers reported votes at this meeting in the year to 30 June 2024. The items are in ballot order: the company's items first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting. The meeting page has the split by reported shares and a CSV file.

  1. Item 1: Director elections

    3 nominees. 77.0% of the reported votes are for. 30 filers withheld from or voted against at least one nominee.

    402 vote records from 83 filers. 22 of the 83 filers that marked the item voted against management.

    • Positions of 31 fund families
    • For 22
    • Abstain or withhold 9
    • Against management 9
  2. Item 2: Advisory vote on executive pay (say-on-pay)

    354 vote records from 263 filers. 69 of the 249 filers that marked the item voted against management. 14 filers gave no management mark.

    • Positions of 38 fund families
    • For 28
    • Against 10
    • Against management 10
  3. Item 3: Audit-related items (auditor ratification)

    134 vote records from 83 filers. 1 of the 83 filers that marked the item voted against management.

    • Positions of 31 fund families
    • For 31

Positions of the fund families at the meeting of 1 May 2024

A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.

KeyForAgainstAbstain or withholdSplit or no voteAgainst management

Fund families at Revance Therapeutics, Inc., meeting of 1 May 2024Families in name order. "Abstain" includes withhold. "Split" includes no vote. "No report" means that no filer of the family listed the item.
Fund familySay-on-pay
AllianceBernsteinFor
BairdFor
BlackRock and iSharesFor
BNY MellonFor
Brighthouse FundsFor
Capital Group and American FundsFor
Charles SchwabFor
Columbia ThreadneedleFor
DimensionalAgainst, against management
DWSFor
EquitableFor
Federated HermesFor
FidelityFor
Franklin TempletonAgainst, against management
Global XAgainst, against management
Goldman SachsFor
Guggenheim and RydexFor
InvescoFor
J.P. MorganAgainst, against management
Jackson National fundsAgainst, against management
Janus HendersonFor
John Hancock and ManulifeFor
Lincoln FinancialFor
Morgan Stanley, Eaton Vance and CalvertFor
NationwideAgainst, against management
Neuberger BermanAgainst, against management
Northern Trust and FlexSharesFor
Nuveen and TIAAFor
Pacific Life fundsFor
PGIM and PrudentialAgainst, against management
PrincipalFor
ProShares and ProFundsFor
SEIAgainst, against management
State Street and SPDRFor
T. Rowe PriceFor
VanguardFor
Victory CapitalFor
VoyaAgainst, against management

Every meeting on file

Meetings of Revance Therapeutics, Inc., from Form N-PX filings, newest firstA meeting with 20 or more reporting filers has its own page. Dates up to three days apart count as one meeting.
MeetingSeasonFilers reportingItemsFilers against management on say-on-pay
year to 30 June 2024266327.7%

Say-on-pay, season by season

Say-on-pay at Revance Therapeutics, Inc.: filers reporting on Form N-PXThe share of filers, and of the shares they reported, that voted against management.
SeasonFilers reportingFilers against managementReported shares against management
year to 30 June 202426827.7%19.8%
Revance Therapeutics, Inc. and the median of companies on this site, year to 30 June 2024
Say-on-payThis companyMedian of companies on this site
Filers against management27.7%7.5%
Reported shares against management19.8%2.9%

The median covers 3,781 companies. Each has a say-on-pay item that 20 or more filers reported. The two figures are not a grade. The median is a reference only.

Vote records at Revance Therapeutics, Inc. by category, every seasonThe category is the one each filer chose.
CategoryVote recordsShare
DIRECTOR ELECTIONS40245.2%
SECTION 14A SAY-ON-PAY VOTES35439.8%
AUDIT-RELATED13415.1%

The record at the SEC

Each link loaded on .

Cite this page

Vote Scores. How funds voted at Revance Therapeutics, Inc.. https://votescores.com/company/revance-therapeutics-inc/. Source: SEC EDGAR, Form N-PX and N-PX/A filings read through .

Questions

How many meetings of Revance Therapeutics, Inc. are on file?
1 meeting is on file, on 1 May 2024. 1 meeting has 20 or more reporting filers and has its own page.
Did filers report proposals from security holders at Revance Therapeutics, Inc.?
Not enough filers reported a proposal from security holders for the site to show one in the year to 30 June 2024. The ballot shows the items that filers did report.
Is this the meeting result?
No. The figures count the filers that report on Form N-PX and the shares they reported. Other holders are not in the count. Revance Therapeutics, Inc. reports the result of a vote on Form 8-K.
How does the site group meetings and names?
Filers type company names and meeting dates themselves. The site groups spellings of one company name. It treats meeting dates up to three days apart as one meeting. The data runs through 13 Nov 2026.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Revance Therapeutics, Inc., grouped by company. The name is the most common spelling among filers. The filers wrote the filings. Filings read through .